Kymera Therapeutics

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Read more

Discovery and targeted mass spectrometry-based proteomics: Enabling technologies advancing IRAK4 protein degrader along the drug discovery pipeline into the clinic

Read more

Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets

Read more

Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition

Read more

European Protein Degradation Congress, September 21st-23rd, 2021

Read more

The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation

Read more

16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021

Read more

American Association of Immunologists’ Virtual IMMUNOLOGY2021™ Annual Meeting, May 10 – 15, 2021

Read more

Society for Investigative Dermatology (SID) 2021 Annual Meeting, May 3-8, 2021

Read more

2nd Annual North American Protein Degradation Congress, February 16-24, 2021

Read more